NASDAQ:ISEE IVERIC bio (ISEE) Stock Price, News & Analysis → Trump’s Gift Could Unleash $51 Billion in New Wealth (From Wealthpin Pro) (Ad) Free ISEE Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$39.95▼$39.9550-Day Range$36.90▼$39.9552-Week Range$9.39▼$39.99VolumeN/AAverage Volume3.62 million shsMarket Capitalization$5.50 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get IVERIC bio alerts: Email Address Ad Wealthpin ProTrump’s Gift Could Unleash $51 Billion in New WealthIn January 2021, Donald Trump silently rolled out a special gift to the American public… One that top house republicans called “The Key To America’s Economic Future”.You just have to make this simple move before July 30, 2024. About IVERIC bio Stock (NASDAQ:ISEE)IVERIC bio, Inc., a biopharmaceutical company, focuses on the discovery and development of novel treatments for retinal diseases with unmet medical needs. The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD); and STAR or OPH2005 that is in Phase 2b clinical trial for the treatment of autosomal recessive Stargardt disease. Its preclinical product candidatures include IC-500, a high temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases. The company also develops OPH2001 that has completed Phase 1/2a clinical trial of various doses of avacincaptad pegol (ACP) administered as a monotherapy for the treatment of GA; OPH2000, which has completed Phase 1/2a clinical trial of various doses of ACP administered in combination with Lucentis for the treatment of wet AMD; OPH2007 that has completed Phase 2a clinical trial for the treatment of wet AMD; and OPH2002, which has completed Phase 2a clinical trial for the treatment of idiopathic polypoidal choroidal vasculopathy. In addition, its minigene programs comprises miniCEP290 program for LCA10; miniABCA4 Program for STGD1; and miniUSH2A Program for usher syndrome type 2A-Related inherited retinal diseases (IRDs). The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. The company was incorporated in 2007 and is based in Parsippany, New Jersey. As of July 11, 2023, IVERIC bio, Inc. operates as a subsidiary of Astellas US Holding, Inc.Read More Ad Wealthpin ProTrump’s Gift Could Unleash $51 Billion in New WealthIn January 2021, Donald Trump silently rolled out a special gift to the American public… One that top house republicans called “The Key To America’s Economic Future”.You just have to make this simple move before July 30, 2024. ISEE Stock News HeadlinesMarch 10, 2024 | investing.comAstellas Pharma Inc (ALPMY)December 15, 2023 | msn.comApellis falls on potential EU snub for eye therapy (update)December 7, 2023 | seekingalpha.comAkoya Biosciences: 2024 Could Be The Year To Own Their StockDecember 1, 2023 | msn.comApellis adds safety warning to eye therapyJuly 11, 2023 | finance.yahoo.comAstellas Completes Acquisition of Iveric BioJune 30, 2023 | markets.businessinsider.comB.Riley Financial Sticks to Its Hold Rating for IVERIC bio (ISEE)May 30, 2023 | seekingalpha.comIveric bio, Still A 5+% OpportunityMay 30, 2023 | finance.yahoo.comAnnexon (ANNX) Stock Down More Than 50% Last Week: Here's WhyMay 23, 2023 | seekingalpha.comBayer, Amgen looked at Iveric before agreeing to Astellas sale - reportMay 17, 2023 | msn.comUnusual Call Option Trade in IVERIC bio (ISEE) Worth $1,780.50KMay 11, 2023 | fool.comIVERIC Bio (NASDAQ: ISEE)May 9, 2023 | msn.comTD Cowen Downgrades IVERIC bio (ISEE)May 2, 2023 | marketwatch.comSHAREHOLDER ALERT: Weiss Law Investigates IVERIC bio, Inc.May 2, 2023 | benzinga.comMoore Kuehn Encourages ISEE, MDWT, CBOF, and SGEN Investors to Contact Law FirmMay 1, 2023 | benzinga.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating IVERIC bio, Inc. BuyoutMay 1, 2023 | benzinga.comCheck Out What Whales Are Doing With ISEEMay 1, 2023 | finance.yahoo.comAstellas Pharma Acquires Iveric Bio For $5.9B To Focus On 'Blindness & Regeneration'May 1, 2023 | finance.yahoo.comBiotech Buying Bonanza: Iveric Bio Snags $5.9 Billion Deal From Astellas PharmaMay 1, 2023 | finance.yahoo.comThese Stocks Are Moving the Most Today: First Republic, JPMorgan, Iveric Bio, SoFi, ON Semi, and MoreMay 1, 2023 | finance.yahoo.comFirst Republic Folds Amid Banking Crisis, Elon Musk Expects Starship To Make Orbit On Next Launch, DOJ Probes Mastercard Over Anti-Competitive Debit-Card Practices: Today's Top StoriesMay 1, 2023 | benzinga.comShareholder Alert: Ademi LLP investigates whether IVERIC bio, Inc. has obtained a Fair Price in its transaction with AstellasMay 1, 2023 | technews.tmcnet.comISEE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Iveric bio, Inc. Is Fair to ShareholdersMay 1, 2023 | marketwatch.comIveric Bio Shares Rise Premarket on Takeover by Astellas >ISEEMay 1, 2023 | msn.comIveric Bio Stock Surges. It's Being Bought by Astellas for $5.9 Billion.May 1, 2023 | finance.yahoo.comJapan’s Astellas to buy US biotech group Iveric Bio for $5.9bnSee More Headlines Receive ISEE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IVERIC bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/01/2023Today6/03/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:ISEE CUSIPN/A CIK1410939 Webivericbio.com Phone(609) 474-6755FaxN/AEmployees163Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.76) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-185,210,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-57.00% Return on Assets-46.15% Debt Debt-to-Equity Ratio0.20 Current Ratio15.53 Quick Ratio15.53 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.43 per share Price / Book9.02Miscellaneous Outstanding Shares137,780,000Free Float134,063,000Market Cap$5.50 billion OptionableOptionable Beta1.06 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Glenn P. Sblendorio M.B.A. (Age 67)CEO & Director Comp: $1.36MDr. Pravin U. Dugel M.D. (Age 59)Pres & Director Comp: $984.82kMr. David F. Carroll M.B.A. (Age 57)Sr. VP, CFO & Treasurer Comp: $725.55kMr. Keith Westby M.B.A. (Age 48)Sr. VP & COO Comp: $701.68kMr. Christopher Paul Simms (Age 48)Sr. VP & Chief Commercial Officer Comp: $715.01kDr. Samir C. Patel (Age 62)Co-Founder and Consultant Dr. Xiao-Ping Dai Ph.D.Chief Technical OfficerMs. Kathy GalanteSr. VP of Investor Relations & Corp. CommunicationsMr. Todd D.C. AndermanSr. VP, Chief Legal Officer & Corp. Sec.Ms. Amy R. SheehanSr. VP & Chief HR OfficerMore ExecutivesKey CompetitorsArdelyxNASDAQ:ARDXMirum PharmaceuticalsNASDAQ:MIRMLarimar TherapeuticsNASDAQ:LRMRXBiotechNASDAQ:XBITProQR TherapeuticsNASDAQ:PRQRView All CompetitorsInsidersKeith WestbySold 20,000 sharesTotal: $789,000.00 ($39.45/share) ISEE Stock Analysis - Frequently Asked Questions How were IVERIC bio's earnings last quarter? IVERIC bio, Inc. (NASDAQ:ISEE) released its quarterly earnings data on Wednesday, March, 1st. The company reported ($0.47) earnings per share for the quarter, missing the consensus estimate of ($0.37) by $0.10. During the same quarter in the previous year, the company posted ($0.29) earnings per share. What is Glenn Spina's approval rating as IVERIC bio's CEO? 6 employees have rated IVERIC bio Chief Executive Officer Glenn Spina on Glassdoor.com. Glenn Spina has an approval rating of 41% among the company's employees. This puts Glenn Spina in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of IVERIC bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other IVERIC bio investors own include Pfizer (PFE), Inovio Pharmaceuticals (INO), Novavax (NVAX), Maxar Technologies (MAXR), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Alibaba Group (BABA), Cisco Systems (CSCO) and Kinross Gold (KGC). This page (NASDAQ:ISEE) was last updated on 6/3/2024 by MarketBeat.com Staff From Our PartnersWho are Nvidia’s Silent Partners?Weiss RatingsWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceThe Only Energy Play You Should Be Looking AtWealthpin Pro[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 MediaPOTUS in ‘25 Not Biden/Trump, ButThe Freeport SocietyCollapse of the Petrodollar Colonial Metals[Webinar] Understanding Covered CallsOICWhat’s Pelosi Buying Now?Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IVERIC bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.